Researchers at Weill Cornell Medical College have discovered why a tiny alteration in a brain gene, found in 20 percent of the population, contributes to the risk for anxiety, depression and memory loss.
Their discovery, reported in Nature Communications, describes new functions for the alteration, a single nucleotide polymorphism (SNP) in the brain-derived neurotrophic factor (BDNF) gene. This gene is a powerful regulator of the growth and function of neurons, and the establishment of brain circuitry. The common alteration occurs when a single "letter" of BDNF's genetic code is "misspelled."
The team of investigators, led by Dr. Clay Bracken, associate research professor of biochemistry and director of the nuclear magnetic resonance facility, Dr. Barbara Hempstead, professor of medicine, and Dr. Francis Lee, professor of psychiatry, all at Weill Cornell Medical College, discovered that the alteration appears to induce shrinkage of neurons from the hippocampus (an important region for memory and emotion), reducing connectivity between brain cells.
The discovery upends the prevailing theory about how the BDNF SNP alters the function of the brain, says Dr. Agustin Anastasia, first author of the article and a postdoctoral fellow in the Hempstead lab. "Research on BDNF is very active worldwide, and the conventional wisdom of the field was that the SNP reduced the amount of BDNF that was secreted. Therefore, many investigators were trying to increase production of the protein -- but this effort was only moderately successful."
"While the SNP does decrease the amount of BDNF in neurons, it generates a protein, the Met66 prodomain, that is different from the Val66 prodomain that is generated by the 80 percent of the human population that does not carry the SNP," Dr. Hempstead says. "The Met66 prodomain binds to specific proteins on the surface of neurons, to induce the pruning or shrinkage of these neurons."
The findings offer mechanistic insight into why some depression and anxiety runs in families, Dr. Lee says. "There can be a heritable component to these diseases and it makes sense that a common variant in a gene could be involved," he says. "Just like hypertension contributes to the risk for heart disease, the BDNF alteration increases the risk of depression, anxiety and memory disorders -- but is not the sole reason why they occur."
Still, targeted treatment for the genetic alteration could provide the first true benefit for affected patients, who often don't respond to traditional treatments, Dr. Lee says. "We can easily test patients for the mutation by using a simple blood test," he says. "We just need novel targeted treatments that alter the effects of the BDNF SNP-- and now we have a good lead on what that therapy should do."The other half of the story
In the new study, the researchers used a combination of approaches to understand what the Met66 prodomain, generated by the BDNF SNP, was doing. Dr. Bracken led the structural biology work that defined the alterations in the protein that were conferred by the BDNF SNP. The team also included Drs. Katrin Deinhardt and Moses Chao, BDNF biologists and investigators from the Skirball Institute at New York University School of Medicine, who used techniques to evaluate neuronal pruning.
The team knew that BDNF is manufactured inside neurons. One part of the protein, the prodomain, was known to help guide BDNF to the surface of neurons. BDNF released from cells stimulates the growth and activity of neighboring neurons. However, little was known about the prodomain itself; it was considered a useless or inactive protein.
The researchers used a variety of methods to study what actually happened to the prodomain with both the altered BDNF (Met66 prodomain), and in wild-type BDNF (Val66 prodomain).
They developed Met66-expressing mice, which displayed many of the detrimental effects (such as anxiety and alterations in memory formation) observed in human Met66 carriers, as well as tests to identify the activity of the Met66 prodomain. The researchers used advanced nuclear magnetic resonance analysis to identify the structure of the Met66 and Val66 prodomains and their interactions, Dr. Bracken says. Human cell lines were used to define the differences in prodomain binding and identify proteins and pathways critical for pruning of neurons.
"This was an exciting collaboration," Dr. Bracken says. "A lot of research studies focus on animal models of human disease, or on biophysics, or on the biology of neurons. We combined all three investigations, which was a very powerful approach because it utilized different ways of thinking about a common problem."
They discovered what they had long suspected but had not previously been able to prove -- that the Met66 prodomain was not an inert protein, but a degenerative agent. The team found that Met66 binds and activates a protein complex (SorCS2 and p75) known to shrink neurons, reducing their ability to communicate with neighboring neurons. They also discovered that the more common Val66 prodomain did not induce neuronal shrinkage.
"This was an unexpected but very exciting result. This study describes how a single substitution in BDNF causes a structural change in Met66 prodomain to endow it with a biological function," Dr. Hempstead says.
"The brain isn't set in stone -- it wants to be able to build and rebuild, and in order to rebuild, it needs to break down neurons first. I suspect that Met66 prodomain is involved in a normal breaking-down process that involves SorC2 and p75, but in the altered BDNF, the balance is shifted in the wrong way," Dr. Lee says.
Using their Met66 mouse model, the researchers are now examining precisely what the mutation does to neurons -- "how it alters the size and length of synapses or changes the way the synapses function," Dr. Anastasia says.
And, with this Met66 mouse model, they can examine drugs that could potentially target Met66 or block the proteins it binds to. "At the end of the day, understanding how the protein is made and how it acts is the goal. This will give us insights into how we can modify the activity of the Met66 prodomain, to help patients with this alteration in BDNF who suffer from anxiety or depression," Dr. Hempstead says.
The research was supported by the National Institutes of Health (NS21072 and HD23315, NS052819, NS030687, NS064114, S10-RR023694) and the Human Frontier Science Program.
Other scientists contributing to the study are Nathan E. Will and Krithi Irmady from Weill Cornell Medical College.
Weill Cornell Medical College
Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston. For more information, visit weill.cornell.edu.Office of External Affairs Weill Cornell Medical College
Sarah Smith | EurekAlert!
A novel socio-ecological approach helps identifying suitable wolf habitats
17.02.2017 | Universität Zürich
New, ultra-flexible probes form reliable, scar-free integration with the brain
16.02.2017 | University of Texas at Austin
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
20.02.2017 | Materials Sciences
20.02.2017 | Health and Medicine
20.02.2017 | Health and Medicine